Cargando…
Effect of educative reminder telephone calls on human papillomavirus immunization rate: A randomized controlled trial
CONTEXT: Human papillomavirus coverage varies widely among women depending on their race, incomes, geographical location and education level. OBJECTIVE: To evaluate whether reminder educative phone calls increase human papillomavirus vaccination rates in adult women aged 18–45 with high-risk factors...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010846/ https://www.ncbi.nlm.nih.gov/pubmed/33779417 http://dx.doi.org/10.1177/17455065211003821 |
_version_ | 1783673139648004096 |
---|---|
author | Bernard-Genest, Marie-Pier Ruel-Laliberté, Jessica Lapointe-Milot, Korine |
author_facet | Bernard-Genest, Marie-Pier Ruel-Laliberté, Jessica Lapointe-Milot, Korine |
author_sort | Bernard-Genest, Marie-Pier |
collection | PubMed |
description | CONTEXT: Human papillomavirus coverage varies widely among women depending on their race, incomes, geographical location and education level. OBJECTIVE: To evaluate whether reminder educative phone calls increase human papillomavirus vaccination rates in adult women aged 18–45 with high-risk factors of cervical cancer. DESIGN: We conducted a single-blind randomized controlled trial in patients who consulted at a Canadian tertiary center in October 2019 during National Cervical Cancer Awareness Week. INTERVENTIONS: We randomized women to receive three standardized educative phone calls or standard care. MAIN OUTCOME MEASURE: We assessed the immunization rate at 6 months. RESULTS: A total of 130 patients were randomized of which 62 patients were randomized to the intervention. Eight patients (15.4%) got immunized at 6 months in the intervention group as compared to seven (11.7%) in the control group (p = 0.5645). The main barrier to vaccination reported by non-immunized patients at 6 months was the cost of vaccination (42.3%). CONCLUSION: Reminder educative phone calls did not increase human papillomavirus vaccination rates in adult women with risk factors of cervical cancer. ISRCTN registration number: ISRCTN58518971 |
format | Online Article Text |
id | pubmed-8010846 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-80108462021-04-13 Effect of educative reminder telephone calls on human papillomavirus immunization rate: A randomized controlled trial Bernard-Genest, Marie-Pier Ruel-Laliberté, Jessica Lapointe-Milot, Korine Womens Health (Lond) Cervical Cancer CONTEXT: Human papillomavirus coverage varies widely among women depending on their race, incomes, geographical location and education level. OBJECTIVE: To evaluate whether reminder educative phone calls increase human papillomavirus vaccination rates in adult women aged 18–45 with high-risk factors of cervical cancer. DESIGN: We conducted a single-blind randomized controlled trial in patients who consulted at a Canadian tertiary center in October 2019 during National Cervical Cancer Awareness Week. INTERVENTIONS: We randomized women to receive three standardized educative phone calls or standard care. MAIN OUTCOME MEASURE: We assessed the immunization rate at 6 months. RESULTS: A total of 130 patients were randomized of which 62 patients were randomized to the intervention. Eight patients (15.4%) got immunized at 6 months in the intervention group as compared to seven (11.7%) in the control group (p = 0.5645). The main barrier to vaccination reported by non-immunized patients at 6 months was the cost of vaccination (42.3%). CONCLUSION: Reminder educative phone calls did not increase human papillomavirus vaccination rates in adult women with risk factors of cervical cancer. ISRCTN registration number: ISRCTN58518971 SAGE Publications 2021-03-27 /pmc/articles/PMC8010846/ /pubmed/33779417 http://dx.doi.org/10.1177/17455065211003821 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Cervical Cancer Bernard-Genest, Marie-Pier Ruel-Laliberté, Jessica Lapointe-Milot, Korine Effect of educative reminder telephone calls on human papillomavirus immunization rate: A randomized controlled trial |
title | Effect of educative reminder telephone calls on human papillomavirus immunization rate: A randomized controlled trial |
title_full | Effect of educative reminder telephone calls on human papillomavirus immunization rate: A randomized controlled trial |
title_fullStr | Effect of educative reminder telephone calls on human papillomavirus immunization rate: A randomized controlled trial |
title_full_unstemmed | Effect of educative reminder telephone calls on human papillomavirus immunization rate: A randomized controlled trial |
title_short | Effect of educative reminder telephone calls on human papillomavirus immunization rate: A randomized controlled trial |
title_sort | effect of educative reminder telephone calls on human papillomavirus immunization rate: a randomized controlled trial |
topic | Cervical Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8010846/ https://www.ncbi.nlm.nih.gov/pubmed/33779417 http://dx.doi.org/10.1177/17455065211003821 |
work_keys_str_mv | AT bernardgenestmariepier effectofeducativeremindertelephonecallsonhumanpapillomavirusimmunizationratearandomizedcontrolledtrial AT ruellalibertejessica effectofeducativeremindertelephonecallsonhumanpapillomavirusimmunizationratearandomizedcontrolledtrial AT lapointemilotkorine effectofeducativeremindertelephonecallsonhumanpapillomavirusimmunizationratearandomizedcontrolledtrial |